Halometasone

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Halometasone

Articles

Most recent articles on Halometasone

Most cited articles on Halometasone

Review articles on Halometasone

Articles on Halometasone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Halometasone

Images of Halometasone

Photos of Halometasone

Podcasts & MP3s on Halometasone

Videos on Halometasone

Evidence Based Medicine

Cochrane Collaboration on Halometasone

Bandolier on Halometasone

TRIP on Halometasone

Clinical Trials

Ongoing Trials on Halometasone at Clinical Trials.gov

Trial results on Halometasone

Clinical Trials on Halometasone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Halometasone

NICE Guidance on Halometasone

NHS PRODIGY Guidance

FDA on Halometasone

CDC on Halometasone

Books

Books on Halometasone

News

Halometasone in the news

Be alerted to news on Halometasone

News trends on Halometasone

Commentary

Blogs on Halometasone

Definitions

Definitions of Halometasone

Patient Resources / Community

Patient resources on Halometasone

Discussion groups on Halometasone

Patient Handouts on Halometasone

Directions to Hospitals Treating Halometasone

Risk calculators and risk factors for Halometasone

Healthcare Provider Resources

Symptoms of Halometasone

Causes & Risk Factors for Halometasone

Diagnostic studies for Halometasone

Treatment of Halometasone

Continuing Medical Education (CME)

CME Programs on Halometasone

International

Halometasone en Espanol

Halometasone en Francais

Business

Halometasone in the Marketplace

Patents on Halometasone

Experimental / Informatics

List of terms related to Halometasone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Halometasone is a potent (Group III) synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other countries such as China, Hong Kong, Turkey, Israel, South Africa and India.

It has been used to treat chronic psoriasis vulgaris[1] and non-infected acute eczematous dermatoses (eczema).[2] One study demonstrated that 0.05% halometasone cream was more effective than 0.05% betamethasone cream in treating dermatitis, though both were well-tolerated with no systemic adverse effects reported.[3]

References

  1. Galbiati, G; Bonfacini, V; Candiani, F (1983). "Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris". The Journal of International Medical Research. 11 Suppl 1: 31–3. PMID 6339290.
  2. Yawalkar, SJ; MacArol, V; Montanari, C (1983). "An overview of international clinical trials with halometasone cream". The Journal of International Medical Research. 11 Suppl 1: 1–7. PMID 6339286.
  3. Schuppli, R; Dressler, H; Yawalkar, SJ; Weirich, EG (1983). "Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate". Zeitschrift fur Hautkrankheiten. 58 (4): 230–7. PMID 6342285.

Linked-in.jpg